Recombinant Human GPR37 Protein, N-GST & C-His from ProteoGenix; catalogue ARO-P11357; research use only.
Know who made it. See the evidence. Buy through one marketplace.
Recombinant Human GPR37 Protein is a protein that is produced through genetic engineering techniques, specifically recombinant DNA technology. It is a member of the G protein-coupled receptor (GPCR) family, which are important signaling molecules involved in a variety of physiological processes. GPR37 is a unique member of this family, as it is predominantly expressed in the nervous system and has been implicated in neurodegenerative diseases such as Parkinson’s disease. In this article, we will explore the structure, activity, and potential applications of this protein.
The gene encoding GPR37 is located on human chromosome 7 and is composed of 13 exons. The protein itself consists of 609 amino acids and has a predicted molecular weight of 67 kDa. It is a transmembrane protein, with seven transmembrane domains that span the cell membrane. The N-terminus of the protein is located on the extracellular side of the membrane, while the C-terminus is located on the intracellular side. This structural arrangement is typical of GPCRs and is essential for their function.
Recombinant Human GPR37 Protein is produced by inserting the gene encoding GPR37 into a suitable expression vector, such as a bacterial or mammalian cell expression system. The protein is then expressed and purified, typically using affinity chromatography techniques. This results in a highly pure and biologically active protein that can be used for various applications.
GPR37 is a GPCR that is activated by a specific ligand, the prosaposin-derived peptide prosaptide. When prosaptide binds to GPR37, it triggers a signaling cascade that leads to the activation of various downstream pathways. One of these pathways is the G protein-coupled receptor kinase (GRK)/β-arrestin pathway, which is involved in regulating GPCR activity and desensitization. GPR37 has also been shown to interact with other proteins, such as the dopamine transporter, and may play a role in regulating dopamine signaling in the brain.
The activity of GPR37 is not fully understood, but it has been implicated in various physiological processes. Studies have shown that GPR37 is highly expressed in the brain, particularly in the substantia nigra, a region that is affected in Parkinson’s disease. It has been suggested that GPR37 may play a role in the maintenance of dopaminergic neurons and may be involved in the pathogenesis of Parkinson’s disease. Additionally, GPR37 has been linked to other neurological disorders, such as Alzheimer’s disease, and may also play a role in immune system regulation.
Recombinant Human GPR37 Protein has potential applications in both research and therapeutics. As a research tool, it can be used to study the structure and function of GPR37 and its interactions with other proteins. It can also be used to investigate the role of GPR37 in various physiological processes and disease states. Furthermore, recombinant GPR37 can be used to develop high-throughput screening assays for potential GPR37-targeted drugs.
In terms of therapeutics, GPR37 has been identified as a potential target for the treatment of Parkinson’s disease. Recombinant Human GPR37 Protein can be used to develop drugs that target this receptor and modulate its activity. Additionally, GPR37 may have potential applications in other neurological disorders and immune-related diseases, making it a promising target for drug development.
In conclusion, Recombinant Human GPR37 Protein is a unique member of the GPCR family that has been implicated in various physiological processes and disease states. Its structure and activity make it a valuable research tool and a potential target for ther
ProteoGenix catalogue number ARO-P11357. For research use only.
Host: Escherichia coli (E.coli); Expression system: Prokaryotic expression; Molecular weight: 32.97 kDa; Fragment: Arg401-Leu443; Buffer: Lyophilized from a solution in PBS pH 7.4, 0.02% NLS, 1mM EDTA, 4% Trehalose, 1% Mannitol..
Available configurations: 50ug, 100ug, 1mg.
This product is manufactured by ProteoGenix and sold through ABMIUM without relabelling.
ABMIUM supports global orders. Availability, shipping requirements and applicable import arrangements are confirmed before fulfilment where required.
Yes. Send your target, sample, application and experimental conditions through ABMIUM MATCH or technical support.
Unless the listing expressly states otherwise, ABMIUM products are supplied for research use only and are not for diagnostic or therapeutic use.
